NCT05682560View on ClinicalTrials.gov

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

July 26, 2024

Study Completion Date

February 27, 2025

Conditions
Long COVIDPost-COVID SyndromePost COVID-19 Condition
Interventions
BIOLOGICAL

REGENECYTE

HPC, Cord Blood

BIOLOGICAL

Placebo

Normal Saline

Trial Locations (1)

33016

Myrak Research Center, Miami Lakes

All Listed Sponsors
collaborator

StemCyte Taiwan Co., Ltd.

INDUSTRY

lead

StemCyte, Inc.

INDUSTRY

NCT05682560 - Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome | Biotech Hunter | Biotech Hunter